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Impaired glucose metabolism, decreased levels of thiamine and its phosphate esters, and reduced 
activity of thiamine-dependent enzymes, such as pyruvate dehydrogenase, alpha-ketoglutarate 
dehydrogenase, and transketolase occur in Alzheimer’s disease (AD). Thiamine deficiency 
exacerbates amyloid beta (Aβ) deposition, tau hyperphosphorylation, and oxidative stress. 
Benfotiamine (BFT) rescued cognitive deficits and reduced Aβ burden in APP/PS1 mice. In this 
study, we examined whether BFT confers neuroprotection against tau phosphorylation and the 
generation of neurofibrillary tangles (NFTs) in the P301S mouse model of tauopathy. Chronic 
dietary treatment with BFT increased lifespan, improved behavior, reduced glycated tau, 
decreased NFTs, and prevented death of motor neurons. BFT administration significantly 
ameliorated mitochondrial dysfunction and attenuated oxidative damage and inflammation. We 
found that BFT and its metabolites (but not thiamine) trigger the expression of Nrf2/ARE-
dependent genes in mouse brain as well as in wild-type but not Nrf2-deficient fibroblasts. Active 
metabolites were more potent in activating the Nrf2 target genes than the parent molecule BFT. 
Docking studies showed that BFT and its metabolites (but not thiamine) bind to Keap1 with high 
affinity. These findings demonstrate that BFT activates the Nrf2/ARE pathway and is a 
promising therapeutic agent for the treatment of diseases with tau pathology, such as AD, 
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Thiamine (vitamin B1) plays a central role in brain energy metabolism. Thiamine diphosphate 
(ThDP) is an essential cofactor of alpha-ketoglutarate dehydrogenase complex, pyruvate 
dehydrogenase complex, and transketolase. ThDP is the most abundant derivative in the brain 
and other tissues, while free thiamine and other phosphorylated derivatives (thiamine 
monophosphate, ThMP and thiamine triphosphate, ThTP) may be important for other brain 
functions (1-4). Accumulating evidence has demonstrated that thiamine deficiency plays a 
central role in the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease 
(AD) (5, 6). A marked reduction in thiamine, its derivatives, and thiamine-dependent enzymes 
has been detected in plasma, red blood cells (5, 7, 8), cerebrospinal fluid (9), and postmortem 
brain tissue from AD patients (5, 10-12).  
There is an established correlation between the decrease of thiamine-dependent processes 
and the severity of dementia in AD subjects (13). Thiamine deficiency accelerated amyloid 
plaque deposition, increased amyloid beta (Aβ)1-42, β-carboxyterminal fragment (C99) and 
BACE levels, and exacerbated oxidative stress and inflammation in Tg19959 transgenic (TG) 
mice overexpressing a double mutant form of the human amyloid precursor protein (APP) (14). 
Clinical trials of thiamine replacement, as a treatment in AD patients, however were 
inconclusive, showing either a mild beneficial effect or no effect on cognition (15-17). 
Oxidative stress is involved in the onset and progression of several neurodegenerative 
diseases, including AD (18, 19). Thiamine deficiency mimics important aspects of oxidative 
stress in AD. Thiamine-deficient mice show elevated malondialdehyde and 3-nitrotyrosine and 
reduced catalase, superoxide dismutase, and glutathione peroxidase activities (20, 21). Oxidative 
stress may result from several interconnected causes, such as mitochondrial dysfunction or 
inflammation, which are processes that occur in the brains of thiamine-deficient animals (22). 
Benfotiamine (BFT), is a synthetic S-acyl derivative of thiamine with an open-ringed 
structure that enhances thiamine bioavailability by ~five-fold as assessed by plasma levels (23). 
BFT prevents the formation of advanced glycation end products and has beneficial effects in 
experimental models of diabetic retinopathy, nephropathy, and neuropathy (24, 25). In APP/PS1 
mice, BFT was reported to dose-dependently improve behavioral deficits and reduce amyloid 
deposition (26). It was reported that in the brains of mice treated with BFT there was an increase 
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in phosphorylation of glycogen synthase kinase-3 beta, which correlates with decreases in its 
activity. These authors reported that BFT decreased the number of phosphorylated tau-positive 
cells in APP/PS1 mice after 8-week treatment in a dose-dependent fashion. It however did not 
comment on NFTs, which were not observed in the initial description of the APP/PS1 mice or in 
subsequent reports (27, 28). It is therefore uncertain whether BFT reduces NFTs, which is an 
important issue since the cognitive deficits encountered in AD correlate better with numbers of 
NFTs, and loss of synapses than with amyloid plaques (29, 30).  
The development of therapeutic interventions targeting tau pathology in AD and 
frontotemporal dementia is of great interest. We therefore evaluated the neuroprotective effects 
of BFT in the P301S TG mouse model of tauopathy that overexpresses the human tau gene 
harboring the P301S mutation, which causes frontotemporal dementia in man (31, 32). We 
observed neuroprotective effects and provide the first evidence that BFT and its metabolites 




Benfotiamine treatment increases lifespan, ameliorates behavioral deficits, and attenuates 
neuronal death 
To assess the effects of BFT on lifespan, a separate cohort of TG mice were fed with BFT or 
control diet until natural death. BFT-treated P301S TG mice lived significantly longer than their 
TG littermates fed with a control diet (average of 390 vs 322 days; 21% increase in longevity) 
(Figure 1B), although no changes in body weight were observed (Figure 1A). To study 
behavioral deficits, P301S TG mice were assessed at 5, 7, and 9 months of age using the elevated 
plus maze (to assess anxiety-like behavior) (Figure 1C) and at 9 months of age using the 
contextual fear conditioning (to assess associative fear learning and memory) (Figure 1D). TG 
mice showed enhanced hyperactivity and disinhibition as well as memory impairment relative to 
WT mice. Nevertheless, these behavioral deficits were rescued in TG mice treated with BFT. 
During the training period, all mice were able to learn the task and freeze after two electric 
shocks. Hind limb paralysis is a distinctive feature of TG mice at late-stage disease (32, 33). To 
determine the effects of BFT on cell death, L3‒L6 regions of the spinal cord, which contain 
motor neuron pools for the hind limbs, were stained with cresyl violet and subjected to 
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stereological neuron counting (Figures 1E-G). The number of SMI32-positive neurons was also 
assessed (Figures 1H-J). We found a significant preservation of motor neurons in TG mice 
treated with BFT relative to TG mice on a control diet.  
 
Tau pathology is reduced following benfotiamine administration 
Tau pathology was assessed using an AT8 antibody that detects phosphorylated tau in NFTs 
(Figure 2). A marked decrement in AT8 immunoreactivity, with a subsequent reduction in tau 
hyperphosphorylation, was detected in both the cerebral cortex (Figure 2A; 1.26 ± 0.44 vs 0.46 
± 0.07 percent area, p< 0.05) and hippocampus (Figure 2B; 5.53 ± 1.44 vs 2.17 ± 0.76 percent 
area, p< 0.05) of P301S TG mice treated with BFT relative to mice on a control diet. Due to its 
involvement in tau phosphorylation, the protein levels of phosphorylated glycogen synthase 
kinase-3 beta (GSK-3β) were also examined by Western blot (26, 34). No alterations were found 
in phospho-GSK-3β expression following BFT treatment in the brain cortical tissue homogenates 
of TG mice (Supplementary Figure 1). 
 
Benfotiamine increases thiamine levels in both the CNS and periphery 
Levels of thiamine and its phosphorylated derivatives were measured in the CNS (cerebral cortex 
and hippocampus), liver, and blood of WT and TG 10-month-old mice (Figure 3). In blood and 
liver, administration of BFT increased the levels of free thiamine, ThMP, and ThDP (Figure 3C 
and 3D). The brain levels of thiamine, ThMP, and ThDP are much lower, and the brain response 
to BFT is much less than that in the blood and liver. Thiamine and ThMP levels were 
significantly elevated in the cerebral cortex and the hippocampus of WT mice while no changes 
were observed in TG mice (Figure 3A and 3B). ThDP levels were variable among groups. 
Thiamine and its derivatives were also assessed in the spinal cord, but no differences occurred 
amongst the groups (data not shown). 
 
Benfotiamine administration improves mitochondrial function 
We examined whether BFT ameliorated mitochondrial dysfunction in P301S TG mice (Figure 
4). Thus, several important mitochondrial antioxidant enzymes were analyzed. Mitochondrial 
complex I protein levels were decreased in TG as compared to WT mice (p< 0.05) and treatment 
with BFT induced a marked increase in complex I immunoreactivity (p< 0.01) (Figure 4A). The 
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enzyme activity of the thiamine-dependent enzymes TK and α-KGDHC were also evaluated in 
the mouse cerebral cortex. TK activity was significantly reduced in TG mice receiving the 
control diet as compared to WT littermates (Figure 4B; 9.9 ± 0.3 vs 7.4 ± 0.8 mU/mg protein, p< 
0.001). The reduced TK levels were significantly increased in P301S TG mice after BFT 
treatment, restoring them to those seen in the control group (7.4 ± 0.8 vs 9.1 ± 0.3 mU/mg 
protein, p< 0.05). Though not statistically significant, there was a trend towards a higher α-
KGDHC activity in TG mice treated with BFT relative to TG mice on the control diet (Figure 
4C). The SOD enzymatic activity was decreased by ~50% in TG mice on the control diet while 
BFT long-term exposure increased the levels of SOD by ~70% (Figure 4D). Interestingly, the 
levels of PGC-1α were reduced in TG mice compared to WT littermates (~85%) and BFT 
administration resulted in an upregulation of PGC-1α mRNA levels in P301S TG mice (Figure 
4E). There was a significant increase in the mtDNA copy number in P301S TG mice treated with 
BFT (Figure 4F; p< 0.05), consistent with the finding that BFT increases PGC-1α levels and 
stimulates mitochondrial biogenesis. 
The dynamin-related protein DRP1 is involved in mitochondrial fragmentation and 
abnormal mitochondrial dynamics in neurodegenerative diseases. Immunohistochemistry 
revealed higher DRP1 immunoreactivity in motor neurons in the ventral horn of the lumbar 
spinal cord of untreated TG mice relative to WT littermates. Administration of BFT diminished 
DRP1 expression in P301S TG mice (Figure 4G). Complex II activity and the expression of the 
non-thiamine dependent mitochondrial electron transport chain enzyme complexes III, IV, and 
FoF1 ATP synthase remained unaltered by BFT treatment in either TG or WT mice 
(Supplementary Figure 2A-D, respectively). No significant alterations were observed in either 
CS activity (the initial enzyme of the TCA cycle) or TFAM mRNA levels (a transcription factor 
for mtDNA) after BFT treatment (Supplementary Figure 2E and F). 
 
Benfotiamine treatment reduced advanced glycation end products (AGEs)  
To evaluate AGEs, tissue sections were immunostained using an antibody directed against 
carboxymethyl lysine (CML), one of the most abundant and well-established AGEs (Figure 5). 
CML immunoreactivity was significantly enhanced in the CNS and motor neurons of the lumbar 
spinal cord of non-treated P301S TG mice compared to WT CTL mice. Quantitative analysis 
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revealed that BFT treatment significantly decreased CML expression in the cerebral cortex 
(Figure 5A5), hippocampus (Figure 5B5), and spinal cord (Figure 5C5) of TG mice.  
 
Long-term exposure to BFT reduces oxidative and nitrosative stress 
To assess oxidative damage, spinal cord sections were stained using antibodies that specifically 
recognize 3-NT (to evaluate protein tyrosine nitration) and 4-HNE (to examine lipid 
peroxidation) (35, 36). Immunofluorescent micrographs at 40x depicted a faint 3-NT 
fluorescence signal (Supplementary Figure 3A2 and A6) and weak 4-HNE staining 
(Supplementary Figure 3A3 and A7) in the motor neurons (anti-choline acetyltransferase 
antibody ChAT) of WT mice. The staining for 3-NT and 4-HNE was significantly increased in 
TG mice (Figure 6A2 and A3). BFT administration led to a significant reduction in the 
fluorescence signal for both 3-NT and 4-HNE (Figure 6A6 and A7) and was quantified for 3-NT 
(Figure 6B, p< 0.05) and 4-HNE (Figure 6C, p< 0.01).  
 SOD-1 is the intracellular SOD which reduces the superoxide of the mitochondrial 
intermembrane space and cytosol to H2O2, whereas SOD-2 is found within mitochondria. SOD1-
derived H2O2 functions as a second messenger to regulate various signal transduction pathways 
involved in inflammation. In this study, we examined the endogenous protein levels of cytosolic 
SOD-1 (Figure 6D and S3B). Confocal analysis revealed a significant decrease in SOD-1 
immunoreactivity in the spinal cord motor neurons of TG mice while BFT treatment 
significantly elevated SOD-1 levels (Figure 6E; 40 ± 3 vs 49 ± 2 fluorescence units, p< 0.05). 
Thioredoxin genes are also important for protection against oxidative stress. Cytosolic 
TRX-1 deficiency could contribute to enhanced oxidative damage and neuronal degeneration in 
AD. Our results demonstrated that chronic exposure to BFT caused a significant increase in 
TRX-1 mRNA levels in P301S TG mice relative to TG mice on the control diet (Figure 6F; 0.9 
± 0.03 vs 1.2 ± 0.05-fold change, p< 0.01). NQO1 is a cytosolic flavoprotein that catalyzes the 
two-electron reduction of quinones and derivates, protecting against ROS production. Exposure 
to BFT upregulated the mRNA levels of NQO1 in TG mice (Figure 6G; 0.89 ± 0.14 vs 1.61 ± 
0.21-fold change, p< 0.05). 
To further assess oxidative damage, levels of protein carbonyls, a standard marker of 
oxidative damage to proteins, were determined in the cerebral cortex of the P301S TG mice 
(Supplementary Figure 3C). Protein carbonyl levels were significantly elevated in P301S TG 
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mice on a control diet relative to their WT littermates (p< 0.05) but were reduced in TG mice 
given BFT treatment. Lastly, mRNA levels of HO1, a putative marker of oxidative injury, were 
assessed (Supplementary Figure 3D). Enhanced levels of HO1 have been reported in patients 
with corticobasal degeneration and Pick’s disease (37). Consistently, our findings demonstrated a 
marked increase in HO1 mRNA levels in P301S TG mice, which were significantly reduced 
following BFT administration. 
 
Benfotiamine mitigates the inflammatory response  
As a consequence of innate immune activation, increased levels of proinflammatory mediators 
have been reported in neurodegenerative disorders. Upregulated iNOS expression has been 
described in postmortem brain specimens of AD subjects. Herein, we investigated the effects of 
BFT on iNOS levels (Figure 7A and Supplementary Figure 4A). Fluorescence confocal 
images depicted an elevated iNOS immunoreactivity within spinal cord motor neurons of TG 
mice on a control diet (Figure 7A2). Exposure to BFT resulted in a significant reduction of 
iNOS expression in P301S mice (Figure 7A5). Quantification of iNOS fluorescence intensity 
(Figure 7B, p< 0.01) and mRNA levels (Figure 7C, p< 0.01) showed significant decreases. We 
also examined the effects of BFT on the expression of other inflammatory mediators (Figure 
7D-I and Supplementary Figure 4B-C). Our findings showed that BFT treatment induced a 
significant decrease in COX-2 (Figure 7E, p< 0.05), TNF-α (Figure 7F, p< 0.05), IL-1β (Figure 
7H, p< 0.05), and NF-κB p65 (Figure 7I, p< 0.01) immunoreactivity in motor neurons of the 
spinal cord in P301S TG mice compared to TG mice on control diet.  
 
Benfotiamine stimulates the Nrf2/ARE pathway 
The Nrf2/ARE signaling pathway has a pivotal role in the regulation of genes involved in 
detoxication of ROS and cytotoxic electrophiles. The Nrf2/ARE transcriptional pathway 
increases protein chaperones, antioxidant enzymes and glutathione synthesis, and reduces COX-
2 and iNOS (38, 39). We therefore examined whether BFT could activate the Nrf2/ARE pathway 
in WT and Nrf2-deficient fibroblasts (Figure 8). BFT administration induced transcription of 
four prototypical genes controlled by the Nrf2/ARE pathway: GSR, HO1, GCLM, and NQO1 in 
WT but not in Nrf2 KO MEFs (Figure 8A). WT MEFs treated with 100 µM BFT for 3 h had 
significantly increased GSR and HO1 mRNA levels. Addition of 50 or 100 µM BFT for 8 h 
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elevated GCLM and NQO1 mRNA levels compared to WT MEFs treated with vehicle, which 
remained unchanged in Nrf2 KO MEFs. None of the genes examined showed a response to 
thiamine except for GSR at the highest dose (100 µM) after 8 h treatment (Figure 8B). These 
findings indicate that BFT can activate Nrf2/ARE genes in WT but not in Nrf2-deficient 
fibroblasts. 
 
Neh2-luc reporter activation by benfotiamine and its metabolites and docking studies 
BFT is a chemical compound containing a phosphate moiety. In order to enter the cell, the 
phosphate moiety has to be removed by enzymatic reactions, which include alkaline phosphatase 
and ectonucleotidase enzymes. BFT decomposes to intermediary metabolites (that possess 
cellular permeability) and is ultimately converted into thiamine (40). These intermediary 
metabolites (s-BT and o-BT along with a plausible impurity z-BT) were obtained from Hamari 
Chemicals (San Diego Research Center, SD, USA) and tested in a Neh2-luc in vitro reporter 
assay. The Neh2-luc reporter is a sensitive assay to monitor the direct effects of chemical entities 
which affect Nrf2 stability by modulating Nrf2/Keap1 and/or Keap-Cul3 interactions (41). BFT, 
s-BT, o-BT, and z-BT (but not thiamine) showed potent activation of reporter activity in a dose-
dependent manner in the 50-100 µM range (Figure 8C). Interestingly, BFT metabolites showed 
more potent stimulation than BFT itself, with the activation effect decreasing in the order z-BT > 
o-BT = s-BT > BFT. We also tested these compounds in a hypoxia-inducible factor (HIF) ODD-
luc reporter assay (Figure 8D), where none of them showed significant luciferase activity, 
further confirming the specificity of their action on the Neh2-luc reporter. The concentration 
range for the observed Neh2-luc reporter activation by BFT and its metabolites is characteristic 
of that for Nrf2 activators working via the Nrf2 displacement mechanism: cell-permeable 
variants of the Nrf2 peptide activate the ARE-luc reporter with an EC50 of 75 µM (42). Small 
molecules like NMBSA begin to activate the ARE-luc reporter only above 50 µM (43). The 
crystal structure for Keap1 bound NMBSA deposited to the Protein Data Bank (4IQK.pdb) was 
used in computer modeling. The Sum of energies (kcal•mol
-1
) scores obtained for BFT 
metabolites were in the order of z-BT > o-BT > s-BT > cz-BT > NMBSA (Supplementary 
Table 2) and perfectly correlated with the order of Neh2-luc reporter activation. BFT metabolites 
show better scores as compared to NMBSA, suggesting that BFT metabolites can work via a 
displacement mechanism.  
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BFT and its metabolites activate Nrf2 driven ARE genes both in in vitro and in vivo systems 
The reporter activation data were further confirmed by testing the ability of these molecules to 
trigger downstream ARE target genes in WT and Nrf2 KO MEFs. Similar to the Neh2-luc 
reporter activation, 100 µM BFT, s-BT, o-BT, and z-BT (but not thiamine) induced expression 
of downstream ARE genes including HO1, NQO1, and GCLM in WT MEFs (Figure 8E) but no 
effect was seen in Nrf2 KO fibroblasts, thus showing the Nrf2 selectivity of the ARE response 
by these molecules. Thiamine, BFT and its metabolites were assessed in vivo for their ability to 
increase expression of genes known to be activated by the Nrf2/ARE transcription pathway. WT 
C57BL/6 mice were treated for 3 h with either vehicle or 1250 mg/kg of thiamine, BFT, s-BT, o-
BT or z-BT through oral gavage and subjected to gene expression analysis. The active 




Reduced glucose metabolism (that may precede the onset of cognitive dysfunction by 10-15 
years) occurs in a characteristic pattern in AD, corresponding to the default mode network (44), 
an area of reduced activity in the temporal-parietal cortex that preferentially succumbs to atrophy 
and Aβ deposition in AD (45). Glucose metabolism is strongly linked to thiamine-dependent 
pathways including the Krebs cycle and the pentose phosphate pathway, which are impaired in 
AD (5, 6, 13). Exposure to BFT improves cognitive impairment and reduces the amyloid burden 
in APP/PS1 TG mice in a dose-dependent fashion and was reported to diminish tau 
phosphorylation, which was attributed to decreased GSK-3β activity (26). Although BFT was 
reported to reduce tau phosphorylation in neurons in the APP/PS1 TG mice, tau phosphorylation 
has been previously observed in neurites of these mice (27, 28).  
We therefore examined the effects of BFT in P301S TG mice, which have a mutation in 
the human tau gene that is linked to frontotemporal dementia, and which develop early synaptic 
and behavioral impairments accompanied by the presence of NFTs, increased tau 
phosphorylation, mitochondrial abnormalities, oxidative damage, and microglial activation (31, 
32, 46). Chronic BFT treatment significantly improved the survival rate and behavioral deficits 
of the P301S TG mice. The reduced lifespan in P301S is accompanied by hind limb paralysis 
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due to the development of NFTs, and subsequent loss of motor neurons in the lumbar region of 
the spinal cord (32, 33). Our findings demonstrate that BFT treatment significantly decreased the 
numbers of NFTs (hyperphosphorylated tau) in the cerebral cortex (~65%) and hippocampus 
(~60%) of P301S TG mice, and furthermore, it appeared to reduce NFTs in motor neurons which 
were protected against cell death.  
After oral administration, BFT is hydrolyzed in the intestine into the lipophilic s-BT that 
diffuses across the epithelial membranes into the blood or liver, where it is converted into 
thiamine (40). As a result, blood thiamine concentrations reach five-fold higher levels and persist 
longer than after administration of an equivalent dose of thiamine. Nevertheless, the magnitude 
of the rate of thiamine uptake into the brain is limited, in part, by a self-exchange mechanism 
catalyzed by the high affinity thiamine transporter (2). The present study is the first in which the 
effects of long-term BFT administration on brain thiamine and thiamine esters have been 
determined. We showed that BFT increased free thiamine, ThMP, and ThDP levels in the liver 
and blood of P301S TG mice. Thiamine and ThMP levels were significantly elevated in the 
cerebral cortex and the hippocampus of WT mice whereas no changes were found in TG mice, 
and ThDP levels were variable between groups. Our findings are generally consistent with those 
of prior short-term studies (23, 26, 47). 
Mitochondrial impairment is believed to cause or contribute to the development of both 
tau pathology and neurodegenerative diseases (19). Herein, we demonstrate that BFT treatment 
prevented the reduction in complex I expression in the brains of P301S TG mice, although no 
alterations were observed in the other mitochondrial oxidative phosphorylation complexes. 
Reduced concentrations of thiamine in blood and decreased red blood cell TK activity are 
important indicators of thiamine deficiency. The coenzyme ThDP, which is associated with the 
direct oxidative pathway of glucose metabolism, increases TK activity in red blood cells (48). In 
the current study, administration of BFT significantly reversed the reduced TK activity in the 
cerebral cortex of P301S TG mice. The fact that we did not observe a consistent increase in brain 
ThDP levels suggests that enhanced TK activity may not be thiamine cofactor-mediated, or that 
our assay was not able to detect a slight but biologically important upregulation of ThDP (or 
another metabolite). It has recently been shown that TK is under Nrf2 control (49), which may 
very well account for the increase we observed. A number of studies have reported decreased 
expression and enzymatic activity of mitochondrial α-KGDHC in brain and fibroblasts of AD 
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subjects (4, 5). We found a reduction in the enzymatic activity of α-KGDHC in the frontal lobe 
of P301S TG mice, which was restored following BFT treatment. 
To further investigate the relationship between mitochondrial dysfunction and tauopathy-
related pathology, we focused on SOD-2, the main superoxide scavenger in mitochondria. Prior 
studies showed that a reduction in SOD-2 activity accelerated the onset of behavioral 
impairments, reduced dendritic arborization and induced microglial activation in hAPP TG mice 
(50), and it increased amyloid burden and tau phosphorylation in the cerebral cortex of Tg2576 
mice (51). In our study, P301S TG mice had decreased SOD-2 activity, which was restored by 
BFT administration. PGC-1α, which plays a pivotal role in controlling mitochondrial biogenesis 
and ROS suppression, has been implicated in the pathogenesis of several neurodegenerative 
disorders. The amount of PGC-1α mRNA is reduced in postmortem brain samples from AD, 
Parkinson’s disease, and Huntington’s disease patients as compared to age-matched controls (52-
54). PGC-1α-mediated activation of mitochondrial biogenesis results from the co-activation of 
several transcription factors, including NRF1 and NRF2 (55). We found a decrease in the mRNA 
levels of PGC-1α in P301S TG mice, which were restored by BFT administration. 
Mitochondrial DNA copy number is a surrogate marker of mitochondrial biogenesis. 
Systemic accumulation of somatic mtDNA regulatory control region mutations has been reported 
in the frontal cortex of AD and Down syndrome dementia subjects, with a resulting decrease in 
mtDNA copy number and mitochondrial function (56). In our study, BFT significantly increased 
mtDNA copy number by nearly 45% in TG mice. Moreover, mitochondrial dynamic processes 
are critical for the maintenance of mitochondrial morphology, autophagy, and apoptosis. 
Alterations in the balance of fusion and fission events have emerged as a causal factor in 
neurodegeneration. The mitochondrial fission protein DRP1 is involved in several structural 
features of mitochondria, including shape, size, and distribution and it plays a central role in 
mitophagy. An interaction between Aβ and DRP1 was seen in the cerebral cortex of AD patients 
and APP/PS1 TG mice (57). Mitochondrial elongation was found in neuronal populations of both 
Drosophila and TG mouse models of tauopathies due to actin-mediated DRP1 mislocalization 
(58). A recent study in CRND8 APP mice showed that treatment with the mitochondrial fission 
inhibitor mdivi-1 rescued mitochondrial dynamics, reduced amyloid deposition and prevented 
cognitive deficits (59). We observed an increase in DRP1 levels in the P301S TG mice, which 
was reduced by BFT treatment. 
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Experimental evidence suggests that AGEs may contribute to neuronal dysfunction and 
death in both Parkinson’s disease and AD (60). AGEs are present in senile plaques, NFTs, and 
some granulovacuolar degeneration granules (61, 62). The accumulation of AGEs in AD is 
associated with an acceleration of Aβ deposition and tau phosphorylation (63, 64). Intracellular 
AGEs are colocalized with phosphorylated tau and it was suggested that they may precede NFTs 
and play a role in their formation (63-66). AGEs can activate RAGE, a receptor for Aβ, leading 
to GSK-3β activation that can phosphorylate tau (67). Interestingly, BFT can activate the pentose 
phosphate shunt by regulation of TK that results in the conversion of fructose-6-phosphate into 
pentose-5-phosphates and other sugars, preventing the formation of AGEs (24). In our study, 
BFT reduced the immunoreactivity of CML and tau hyperphosphorylation, consistent with a 
beneficial effect. The ability of BFT to activate glyoxalase 1 and reduce AGEs may directly 
contribute to its ability to decrease tau phosphorylation and NFTs. 
A significant amount of evidence has demonstrated that oxidative stress contributes to 
tauopathy-related neurodegeneration. For instance, a marked accumulation of 8-hydroxy-2'-
deoxyguanosine in mtDNA, protein carbonyl formation, and tyrosine nitration have been 
detected in the frontal cortex and hippocampus of AD individuals at different stages of the 
disease (68). Enhanced oxidative stress is present in the frontal cortex, subthalamic nucleus, and 
cerebellum of individuals with progressive supranuclear palsy (69-71). BFT administration for 
two weeks reduced diabetes-induced oxidized glutathione in the cerebral cortex of mice (72). In 
our study, BFT diminished 3-NT and 4-HNE immunoreactivity and protein carbonyls, and 
increased the levels of SOD and other redox proteins, such as TRX-1 and NQO1 in P301S TG 
mice.  
There is evidence linking tau pathology in neurodegenerative diseases to inflammation. A 
substantial increase of several pro-inflammatory mediators, including iNOS, COX-2, TNF-α, IL-
1β and NF-κB has been described in AD (73-75). We previously showed that reduced iNOS is 
beneficial and extends survival in the Tg2576 mouse model of AD (76). Prolonged and 
widespread activation of both astrocytes and microglial cells have been observed in tau-related 
disorders. Recently, it has been reported that the SPI1 gene decreases the expression of the 
transcription factor PU.1, which regulates the expression of multiple AD-related genes in 
microglia and other myeloid cells, and delays the onset of AD (77, 78). Glial activation closely 
correlates with the load and distribution of NFTs in P301S TG mice (32) and elevated levels of 
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IL-1β and COX-2 as well as microglial activation have been observed in both the brain and 
spinal cord (79). BFT exhibits anti-inflammatory properties in LPS-stimulated cells (80, 81). 
Consistent with prior studies, our findings here show that BFT exerts a potent anti-inflammatory 
effect in P301S TG mice, with reductions in iNOS, COX-2, TNF-α, IL-1β, and NF-κB p65 
levels. 
The Nrf2/ARE transcriptional pathway is the master regulator of responses to oxidative 
stress, inflammation and mitochondrial dysfunction. Oxidative stress and/or exposure to 
electrophilic compounds cause the dissociation of the Nrf2-Keap1 complex. Nrf2 then 
translocates to the nucleus where it binds to AREs in the promoter regions of several genes 
involved in antioxidant and anti-inflammatory defenses. Nrf2 has beneficial effects on 
mitochondrial biogenesis and function (82). Activation of Nrf2 also downregulates iNOS and 
COX-2 and reduces AGEs formation through the transcriptional control of glyoxalase 1 (83). 
Nrf2 also increases expression of DNA repair enzymes and proteasome subunits. There is a 
reduction in Nrf2 levels in AD brains (84). Increased expression of Nrf2 in the hippocampus 
using a lentiviral vector improved learning and memory in APP/PS1 mice (85) while a 
deficiency of Nrf2 exacerbates AD-like pathology (86). We previously showed that activation of 
the Nrf2 pathway with triterpenoids was neuroprotective in TG mice with increased amyloid 
production (87). Activation of the Nrf2/ARE pathway attenuated tau-induced microgliosis in the 
hippocampus of mice expressing human P301L tau (88). We also demonstrated that methylene 
blue activates the Nrf2/ARE pathway and prevents tau-related neurotoxicity in the P301S TG 
mice (89) and that Nrf2 activating compounds fumarates increased glutathione synthesizing 
enzymes and protected against MPTP toxicity in WT but not in Nrf2 KO mice (90). 
We therefore tested whether BFT and its metabolites are Nrf2 activators in both cells and 
in the mouse brain. Our data showed that BFT and its metabolites significantly increased the 
expression of Nrf2-dependent genes in WT but not in Nrf2-deficient fibroblasts as well as in 
brain, whereas thiamine had no effect. Moreover, the Neh2-luc reporter data indicate that both 
BFT and its metabolites (s-BT, o-BT and z-BT) are Nrf2 activators working via Nrf2 protein 
stabilization. The BFT metabolites were more potent in activating Nrf2 downstream genes than 
BFT per se. We cannot completely exclude the possibility of mild alkylating properties of these 
BFT metabolites; however, based on the high docking scores obtained in comparison with those 
of NMBSA, it is likely that Nrf2 activation by BFT metabolites occurs by a displacement 
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mechanism. This is advantageous since it avoids the potential toxicity of Nrf2 activators, which 
act by alkylation.  
In summary, our study provides the first evidence that long-term treatment with BFT is 
neuroprotective in a mouse model of tauopathy. Many of the BFT-mediated beneficial effects 
observed in P301S TG mice may be attributable to activation of the Nrf2/ARE pathway. Active 
metabolites were more potent in activating the Nrf2 target genes than the parent molecule BFT. 
These findings demonstrate that BFT (and its metabolites) are of particular interest as potential 
treatments for neurodegenerative disorders in which tau pathology plays a pivotal role, including 
AD, frontotemporal dementia, progressive supranuclear palsy, Pick’s disease, corticobasal 
degeneration, and chronic traumatic encephalopathy. 
 
MATERIALS AND METHODS 
Experimental design 
All offspring were generated by breeding P301S TG male with wild-type (WT) female mice 
obtained from Jackson Laboratory (Bar Harbor, ME, USA), which had the same C57BL/6 x C3H 
background. Animals were genotyped by PCR using genomic DNA extracted from mice tails. 
P301S TG mice and their WT littermates received either ad libitum control diet (LabDiet 5001) 
or diet containing 200 mg/kg/d of BFT (also known as S-benzoylthiamine O-monophosphate), 
which is the dose that produced the greatest efficacy in reducing the amyloid burden in APP/PS1 
TG mice, although these authors administered BFT by gastric gavage daily for 8 weeks (26). In 
our experiments, mice were randomly classified into two groups: cohort 1, assigned to survival 
assessment (mice were kept until natural death); cohort 2, allocated to behavioral, 
histopathological, and biochemical analyses (mice were treated from 1 to 10 months). Behavioral 
tests were performed at 5, 7, and 9 months of age. Histopathological and biochemical analyses 
were conducted at 10 months of age. Both males and females were used equally (1:1 ratio); we 
did not find significant differences between them. All experiments were approved by the Animal 
Care and Use Committees of Weill Cornell Medicine and Augusta University.  
  
Behavioral assessment 
Anxiety was evaluated using a standard elevated plus maze (EPM) test as previously described 
(31). The percentage of time spent in the open arms of the apparatus was calculated over the 5 
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min test. Emotional learning and memory were determined using contextual fear conditioning as 
described elsewhere (91). After the last shock, mice were left in the chamber for 30 s. Contextual 
fear memory was measured by scoring freezing behavior for 180 s when mice were placed back 
into the same conditioning chamber 24 h after training, using the FreezeFrame computerized 
system (Coulbourn Instruments. Allentown, PA, USA).   
 
Tissue preparation 
Half of the mice from each group were deeply anesthetized using sodium pentobarbital and 
transcardially perfused with ice-cold 0.9% sodium chloride and 4% paraformaldehyde (PFA). 
Tissue sections (40 µm-thick) were collected, post-fixed in 4% PFA followed by gradient 
sucrose (15% and 30%), and stored in cryoprotectant for immunohistochemical studies. The 
remaining mice in each group were sacrificed by decapitation; then, the brain and spinal cord 
were collected, snap frozen in liquid nitrogen, and stored at −80 °C for subsequent analysis.  
   
Neurochemistry 
The levels of thiamine, ThDP, and ThMP were measured using high-performance liquid 
chromatography (HPLC) with fluorescent detection in cerebral cortex, hippocampus, liver, and 
blood on frozen samples as previously described (4).  
 
Immunohistochemistry  
Tissue sections for general histology were washed in phosphate-buffered saline (PBS) six times 
(10 min each) and treated with 3% hydrogen peroxide for 10 min. Following three PBS rinses, 
sections were blocked in 10% normal goat serum for 1 h, containing 0.3% triton X-100. Next, 
tissue sections were incubated with primary antibodies (Supplementary Table 1) for 24 h at 4 
°C. After three washes in PBS, sections were incubated at room temperature (RT) for 1 h in 
biotinylated secondary antibody (Supplementary Table 1), rinsed again in PBS, and treated 
with avidin-biotin peroxidase complex solution (Vector, Burlingame, CA, USA). Tissue sections 
were visualized using diaminobenzidine and mounted directly onto slides using Aquamount. 
 Histological quantification was done using an average of four serial non-adjacent sections 
per animal (480 µm apart from bregma regions -1.34 through -2.84). The percent area occupied 
was measured within a 0.9 mm
2 
area using Scion Image (Scion Corp. Frederick, MD, USA). For 
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cerebral cortex, the measurements were made in an area encompassing the M1 (primary) and M2 
(secondary) motor cortex regions with the threshold set at fifty. For the hippocampus, the percent 
area occupied in the CA1 field was measured, using the dentate gyrus as an anatomical 
landmark, with the threshold set at forty.   
For fluorescence analysis, tissue was removed from cryoprotectant and washed six times 
in PBS for 10 min each at RT. After blocking with a solution consisting in 10% normal donkey 
serum in PBS for 1 h, sections were incubated using primary antibodies (Supplementary Table 
1) in PBS with 1% normal donkey serum overnight at 4 ºC. Then, tissue sections were rinsed 3 
times in PBS for 10 min each and subsequently incubated with conjugated secondary antibodies 
(Supplementary Table 1) for 2 h. Lastly, after 3 washes in PBS for 10 min, the samples were 
mounted directly onto plus-coated slides and coverslipped using gelvatol mounting media. 
 
Unbiased stereology 
Spinal cord sections were mounted and immersed in 0.25% cresyl violet solution for 5 min.  
Quantification was done using 8 serial non-adjacent sections per animal (240 µm apart from 
lumbar regions L3-L6). The number of motor neurons (>15 µm diameter) was estimated 
stereologically using the Optical Fractionator (Stereo Investigator, Microbrightfield. Burlington, 
VT, USA). The thickness of the sections was measured by focusing on the top of the section, 
setting the Z-axis to 0, and then refocusing to the bottom of the section. Analysis was carried out 
using a Nikon Plan Fluor 40x objective (NA 0.75) and only the cells with a visible nucleus were 
counted. The counting frame was 75 x 75 x 14 µm (height x width x dissector height) and the 
sampling grid was 150 x 150 µm. The average final section thickness was 20 µm, making the 
average guard zone 3 µm from the top and bottom of the section. An experimenter blinded to the 
treatment group performed all analyses. 
 
Western blotting 
Tissue was homogenized in ice-cold stringent radioimmunoprecipitation assay buffer (1:30 w/v 
RIPA; 50 mM Tris-HCl, pH 8.0, with 150 mM sodium chloride, 1.0% Igepal CA-630 (NP-40), 
0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate) containing the protease and 
phosphatase inhibitors by sonication. Proteins were quantified using the Bradford assay and 
lysates were either used immediately or stored at –80 ºC. Equal amounts of protein were 
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electrophoresed through 4-20% Criterion TGX Gels (Bio-Rad Laboratories, Inc. Hercules, CA, 
USA). Polyvinylidene fluoride membranes were activated in 100% methanol. Protein was 
transferred to membranes and blocked in 5% BSA, 1X tris-buffered saline (TBS), and 0.1% 
Tween-20 and exposed overnight to primary antibody (Supplementary Table 1) in the same 
solution at 4 °C. Membranes were then washed 3 times with TBST and incubated for 1 h with 
HRP-conjugated secondary antibody (Supplementary Table 1). Immunoreactive proteins were 
detected using a chemiluminescent substrate (Pierce, ThermoFisher Scientific. Waltham, MA, 
USA) and analyzed using the NIH-based Scion Image software (Scion Corp. Frederick, MD, 
USA). 
 
Gene expression analysis 
Brain samples were processed for RNA extraction (Qiagen. Valencia, CA, USA). RT-PCR was 
performed using a SYBR Green-based assay on an ABI Prism 7900HT sequence detection 
system (Applied Biosystems. Foster City, CA, USA). Total messenger RNA was analyzed for 
the following genes: peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α), thioredoxin 1 (TRX-1), NAD(P)H dehydrogenase quinone 1 (NQO1), inducible 
nitric oxide synthase (iNOS), mitochondrial transcription factor A (TFAM), heme oxygenase 1 
(HO1), glutathione reductase (GSR), gamma-glutamate-cysteine ligase modifier subunit 
(GCLM), gamma-glutamate-cysteine ligase catalytic subunit (GCLC), and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH, used as an internal control).   
 
High-resolution confocal laser scanning microscopy analysis 
Confocal microscopy was utilized to evaluate the oxidative stress and neuroinflammatory 
responses in the spinal cord of TG mice. Fluorescent images were acquired on a Leica TCS SP5 
confocal microscope under constant power and pinhole aperture and evaluated using the LAS X 
software package. Fluorescence micrographs were obtained with an HCX PL APO CS40x (NA 
1.25) oil-immersion objective lens. To quantitate protein levels, ROIs were outlined around the 
neuronal perikarya. Immunofluorescence intensity was determined for 3-nitrotyrosine (3-NT), 4-
hydroxynonenal (4-HNE), SOD (superoxide dismutase (SOD) 1, peroxiredoxin 3 (PRDX3), 
iNOS, the enzyme cyclooxygenase 2 (COX-2), tumor necrosis factor-α (TNF-α), cytokine 
interleukin-1β (IL-1β), and nuclear factor kappa B (NF-kB) subunit p65.  
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Frontal lobe samples (30-55 mg) were thawed on ice and dispersed using a 2 ml dounce 
homogenizer. The homogenate was centrifuged at 1,000 g x 5 min to get rid of nuclear fraction 
and cell debris. The resulting supernatant was centrifuged at 14,000 g x 5 min. The pellet was 
then collected and centrifuged again at 14,000 g x 5 min. The new obtained pellet was 
resuspended in 20 mM HEPES (pH 7.8) and used in any subsequent experiments. The protein 
lysates containing equal amounts of protein were separated by SDS-PAGE, electroblotted onto a 
nitrocellulose membrane (Bio-Rad. Hercules, CA, USA), and immunoreacted with an 
appropriate primary antibody followed by HRP conjugated secondary antibodies 
(Supplementary Table 1). Immunoreactive proteins were visualized by incubating membranes 
in a chemiluminescence substrate (Pierce Biotechnology. Rockford, IL, USA) and analyzed 
using NIH Image J software.   
Transketolase activity was determined with a coupled enzyme assay in which the glyceraldehyde 
phosphate product was isomerized to dihydroxyacetonephosphate and reduced with NADH (5). 
Alpha-ketoglutarate dehydrogenase (α-KGDHC) complex activity was monitored as the 
ketoglutarate dependent conversion of NAD
+
 to NADH (α-ketoglutarate + NAD
+
 + CoA → 
succinyl CoA + CO2 + NADH) as previously described (5). SOD activity was assessed in semi-
purified mitochondrial fraction (crude mitochondrial fraction, which may contain fragments of 
Endoplasmic Reticulum and microsomes, as it is technically impossible to eliminate these 
contaminants by standard differential centrifugation procedures) using an Enzo Life Sciences kit 
(#ADI-900-157). The succinate dehydrogenase (SDH, complex II) and citrate synthase (CS) 
enzymatic activities were measured by well standardized, published methods (92, 93). All 
activities and content values were normalized by protein content. The protein levels of 
NADH:ubiquinone oxidoreductase (complex I, subunit NDUFB8), coenzyme Q reductase 
(complex III, subunit Core 2), cytochrome c reductase (complex IV, subunit MT-CO1), and ATP 
synthase (ATPase, subunit ATP5A1) were also quantitated by Western blotting.  
 
Mitochondrial DNA copy number 
Tissues were processed for DNA extraction according to the Qiagen manufacturer's protocol 
(Valencia, CA, USA). The relative mtDNA copy number was determined by quantitative RT-
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PCR using the ratio of the mtDNA encoded subunit cytochrome oxidase 2 to the nuclear DNA 
encoded protein β-actin (94) on an ABI PRISM 7900H Sequence Detection System (Applied 
Biosystems) using the TaqMan Universal PCR Master mix and predeveloped TaqMan Gene 
Expression Assay primers/probes (Applied Biosystems). Threshold cycle values were expressed 
as the 2
-∆Ct
 of cytochrome oxidase. 
 
Protein carbonyls 
Carbonylated proteins were detected using an OxyBlot kit reagent (#10005020, Cayman 
Chemical. Ann Arbor, MI, USA). Carbonyl groups were derivatized to 2,4-
dinitrophenylhydrazone (DNP-hydrazone) by reaction with 2,4-dinitrophenylhydrazine (DNPH). 
The DNP-derivatized protein samples were separated by polyacrylamide gel electrophoresis 
followed by Western blotting. Next, immunodetection was performed with a primary antibody 
specific to the DNP moiety of the proteins and subsequent incubation with an HRP-antibody 
conjugate directed against the primary antibody. Blots were developed by using an enhanced 
chemiluminescence method. Densitometric analysis of band intensity was used to quantitate 
protein oxidation.  
 
Computer modeling  
Docking experiments were performed using the CDOCKER algorithm, followed by force field 
minimization and binding energy calculations using the molecular mechanics algorithm 
CHARMm (as implemented in Discovery Studio 2.5, Accelrys. San Diego, CA, USA). The 
crystal structure of human Keap1 Kelch domain with the bound Nrf2 activator working via a 
displacement mechanism, N,N'-naphthalene-1,4-diylbis(4-methoxybenzenesulfonamide), or 
NMBSA (4IQK, docking scores and visualization of data are shown in Supplementary Table 2) 
with hydrogen atoms added was the starting template structure. The docking control was 
performed with NMBSA: the molecule was placed into Keap1 exactly as observed in the crystal 
structure; the docking scores obtained for NMBSA were used for comparison. The docking 
experiments were done with the fixed constraints applied to the protein structure. The phosphate 
group of BFT was removed before docking due to the known BFT in vivo activity only in the 
form of S-benzoylthiamine or S-(2-(N-((4-amino-2-methylpyrimidin-5-yl) methyl) formamido)-
5-hydroxypent-2-en-3-yl) benzothioates-BT (s-BT, the negatively charged phosphate group will 
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not penetrate the cell, moreover BFT will be dephosphorylated in vivo by enzymatic hydrolysis 
to s-BT). For z-BT ((Z)-S-(2-(N-((4-benzamido-2-methylpyrimidin-5-yl)methyl)formamido)-5-
hydroxypent-2-en-3-yl)benzothioate)), docking was also determined for its cyclic form that will 
be generated in vivo, as cz-BT. 
 
Luciferase reporter assays 
Human neuroblastoma SH-SY5Y cells stably expressing Neh2- and ODD-luc reporters were 
plated at a density of 10,000 cells/well and cultured in DMEM/F12 medium supplemented with 
GlutaMAX, containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin (38). 
Thiamine, BFT, s-BT, o-BT (O-benzoylthiamine or (3-[(4-amino-2-methyl-5-pyrimidinyl) 
methyl]-5-[2-(benzoyloxy) ethyl]-4-methyl-thiazolium), and z-BT were tested in 96-well plates 
at two different concentrations (50 and 100 µM) for 6 h. The number of cells was estimated 
using a Presto-Blue cell viability reagent (ThermoFisher Scientific). Next, the medium was 
removed, cells lysed, and luciferase activity was measured on a SpectraMax M5 Microplate 
Reader with BrightGlo reagent (Promega. Madison, WI, USA). The reporter activation was 
normalized to the background luminescence and the cell number. To demonstrate selectivity of 
Nrf2 activation, HIF-1 ODD-luc reporter assay was performed in the presence of BFT and its 
analogues, as previously described (38).  
 
Nrf2-target genes assessment 
Prototypical Nrf2 driven ARE genes were determined following administration of thiamine, 
BFT, s-BT, o-BT or z-BT at a single dose of 1250 mg/kg/day administered in 100 µL of vehicle 
(1% carboxymethyl cellulose solution in glycerol: water (60:40) mixture) by oral gavage. 
Control groups of mice received vehicle (1% carboxymethyl cellulose solution in glycerol: water 
(60:40) mixture) at the same volume. Mice were sacrificed, and the ventral midbrain and liver 
were collected after 3 h of drug administration and processed for RT-PCR analysis. 
 
Fibroblast studies of gene expression 
Both WT and Nrf2 knock-out (KO) mouse embryonic fibroblasts (MEFs) were cultured in 
Isocove’s Modified Dulbecco’s Media supplemented with 10% FBS, 100 U/ml penicillin, and 
100 µg/ml streptomycin in a humidified incubator set at 37 ºC with 5% CO2 in 6-well plates. 
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Cells were treated with 100 µM of either vehicle (pyridine: water mixture; 1:1), thiamine, BFT, 
s-BT, o-BT or z-BT for a total incubation time of 4 h and harvested for real-time PCR. Total 
RNA (0.5 µg) was prepared using Trizol and reverse transcribed using a High Capacity Reverse 
Transcription kit (Life Technologies. Carlsbad, CA, USA). After dilution, 100 ng cDNA were 
used to measure relative gene expression compared to WT control. Specific primers and SYBR 
Select kit (Life Technologies) were used to amplify the cDNA in an ABI Prism 7900HT 
sequence detection system (Applied Biosystems). Relative gene expression was determined 
using the 
∆∆
Ct method with values normalized to GAPDH expression. 
 
Statistical analysis 
GraphPad Prism 7 software was utilized for statistical analysis, which was performed by two-
way ANOVA followed by Tukey or Dunnett’s post-hoc test. Two-tailed unpaired t-test was used 
to compare only two groups (P301S mice fed either control or BFT diets). The cumulative 
survival was plotted using the Kaplan Meier test. Data were expressed as mean ± S.E.M. A value 
of p< 0.05 was considered to be significant for all tests.   
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FIGURE LEGENDS 
Figure 1. Benfotiamine treatment increased lifespan, improved behavioral deficits, and 
prevented motor neuron death in P301S mice. (A) Animal weight. No differences were 
observed following chronic BFT administration. (B) Survival curve. BFT-treated TG mice 
showed a significant increase in lifespan. ** p< 0.01 compared to TG CTL (Gehan-Breslow-
Wilcoxon test). (C) Elevated plus maze and (D) contextual fear conditioning. Long-term 
treatment with BFT enhanced memory and reduced behavioral hyperactivity and disinhibition. 
**** p< 0.0001, *** p< 0.001, ** p< 0.01 and * p< 0.05 relative to WT CTL. ### p< 0.001, ## 
p< 0.01 and # p< 0.05 vs WT BFT. * p< 0.05 compared to TG CTL (two-way ANOVA 
followed by Tukey multiple comparisons test). L3‒L6 regions of the spinal cord, which contain 
motor neuron pools for the hind limbs, were stained with cresyl violet (E-F) and the SMI32 
antibody (H-I), which recognizes an epitope on non-phosphorylated neurofilament of proteins. 
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Stereological counts show a higher number of motor neurons in BTF treated P301S TG mice 
compared to TG mice on a control diet. Quantitative analysis was carried out in eight sections 
per animal. Each treatment group was comprised of six mice. ** p< 0.01 and * p< 0.05 relative 
to TG CTL (unpaired t-test). Scale bar: 200 µm at low magnification and 100 µm at high 
magnification. 
 
Figure 2. Reduced tau pathology following benfotiamine administration. Immunostaining 
with AT8 antibody in the cerebral cortex (A) and hippocampus (B) of WT and TG mice treated 
with BFT or control diet. Calculation of the percent area occupied by AT8-immunopositive 
neurons revealed that BFT significantly reduced tau hyperphosphorylation in the brain of TG 
mice. For all tests, n = 6 for TG CTL and n = 8 for TG BFT. * p< 0.05 compared to TG CTL 
(unpaired t-test). Scale bar: 100 µm. 
 
Figure 3. Levels of thiamine and its metabolites. Content of thiamine, ThMP, and ThDP levels 
in the cerebral cortex (A), hippocampus (B), liver (C), and blood (D) of WT and TG mice. 
Treatment with BFT resulted in elevated levels of thiamine, ThMP, and ThDP in the liver and 
blood of both WT littermates and P301S TG mice. However, BFT only increases the 
concentration of cortical and hippocampal thiamine, ThMP, and ThDP in WT mice but remained 
unchanged in TG mice. The experimental groups were comprised of seven mice for CTL group 
and eight mice for BFT group. **** p< 0.0001, *** p< 0.001, ** p< 0.01 and * p< 0.05 vs WT 
CTL. #### p< 0.001, ### p< 0.001, ## p< 0.01 and # p< 0.05 compared to WT BFT. **** p< 
0.0001, *** p< 0.001, and ** p< 0.01 relative to TG CTL (two-way ANOVA followed by 
Tukey multiple comparisons test). 
 
Figure 4. Benfotiamine restores mitochondrial dysfunction. Frontal lobe samples were used 
to determine the mitochondrial expression of complex I (A), enzymatic activity of TK (B), α-
KGDHC (C), and SOD (D), mRNA levels of PGC-1α (E), and mtDNA copy number (F). TG 
mice fed BFT exhibited a considerable increase in complex I immunoreactivity, enzymatic 
activities, PGC-1α levels, and the copy number of mtDNA. Data are mean ± S.E.M. of six to 
eight mice per group. *** p< 0.001 and * p< 0.05 relative to WT CTL. ## p< 0.01 and # p< 
0.05 vs WT BFT. ** p< 0.01 and * p< 0.05 compared to TG CTL (two-way ANOVA followed 
by Tukey multiple comparisons test). (G) Assessment of DRP1 immunoreactivity in the ventral 
horn of the lumbar spinal cord of WT and TG mice fed control or BFT diets. Insets correspond to 
high magnification images of DRP1 immunoreactivity in individual motor neurons. The 
expression of DRP1 was elevated in untreated P301S TG mice compared to WT mice with or 
without BFT. DRP1 immunoreactivity was robustly decreased by BFT treatment. Scale bar: 100 
µm at low magnification and 25 µm at high magnification. 
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Figure 5. Exposure to benfotiamine prevents the formation of AGEs. CML 
immunoreactivity in the cerebral cortex (A), hippocampus (B), and spinal cord (C) of WT and 
TG mice with or without BFT treatment. There was a substantial decrease in the percent area 
occupied by CML-immunoreactive cells following BFT exposure in P301S TG mice. WT, n = 3-
5; TG, n = 7-10. *** p< 0.001 and * p< 0.05 vs WT CTL. ### p< 0.001 and ## p< 0.01 
compared to WT BFT. *** p< 0.001 relative to TG CTL (two-way ANOVA followed by Tukey 
multiple comparisons test). Scale bar: 100 µm. 
 
Figure 6. Dietary administration of benfotiamine reduces oxidative and nitrosative stress. 
Representative 40x confocal images for 3-NT and 4-HNE immunostaining in spinal cord 
sections (A). BFT treatment resulted in a significant decrease in the immunoreactivity of 3-NT 
and 4-HNE in P301S TG mice compared to TG mice on a control diet (A2-A3 vs A6-A7, 
respectively). Quantification of fluorescence intensity for 3-NT (B) and 4-HNE (C). Histograms 
are representative of the average of 250-300 motor neurons corresponding to four to five sections 
per animal. Results are expressed as the mean ± S.E.M. of four to five mice per group. ** p< 
0.01 and * p< 0.05 compared to TG CTL (unpaired t-test). Scale bar: 25 µm. Immunofluorescent 
micrographs at 40x depicted an enhanced expression of SOD-1 in TG mice treated with BFT 
relative to TG CTL mice (D). The mean fluorescence intensity signal for each ROI was 
determined in spinal cord sections, with data representing the average of 250-300 motor neurons 
corresponding to four to five sections per animal (E). Each group was comprised of four to five 
mice. * p< 0.05 relative to TG CTL (unpaired t-test). Scale bar: 25 µm. Chronic administration 
of BFT upregulated mRNA levels of TRX-1 (F) and NQO1 (G) in P301S TG mice. A total of 
five to six mice from each genotype were used for quantitative analyses. ** p< 0.01 and * p< 
0.05 compared to TG CTL (two-way ANOVA followed by Tukey multiple comparisons test).  
 
Figure 7. Benfotiamine treatment alleviates inflammation. (A) Confocal images depicted a 
marked iNOS immunoreactivity in TG CTL mice but oral administration of BFT significantly 
downregulated iNOS levels (A2 vs A5). (B) Quantification of fluorescence levels of iNOS 
representative of the average of 250-300 motor neurons corresponding to four to five sections per 
animal. Results are expressed as the mean ± S.E.M. of four to five mice per group. ** p< 0.01 vs 
TG CTL (unpaired t-test). Scale bar: 25 µm. (C) Gene expression levels of iNOS in WT and TG 
mice fed either a control or BFT diet. Exposure to BFT caused a robust reduction in iNOS 
mRNA levels in P301S TG mice relative to TG CTL mice. ** p< 0.01 compared to WT CTL. ## 
p< 0.01 vs WT BFT. ** p< 0.01 vs TG CTL (two-way ANOVA followed by Tukey multiple 
comparisons test). (D) Representative immunofluorescence confocal images at 40x for COX-2 
and TNF-α in spinal cord sections. The immunoreactivity of COX-2 and TNF-α was 
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significantly diminished in BFT-treated P301S TG mice relative to TG mice on a control diet 
(D2-D3 vs D6-D7). Quantification of fluorescence intensity for COX-2 levels (E) and TNF-α 
(F). Each bar represents the mean ± S.E.M. of 250-300 motor neurons from four to five sections 
per animal. Each group was comprised of 4-5 mice. * p< 0.05 compared to TG CTL (unpaired t-
test). Scale bar: 25 µm. (G) Confocal micrographs at 40x revealed that TG CTL mice displayed 
higher IL-1β and NF-κB p65 fluorescence intensity, which was substantially reduced following 
BFT treatment (G2-G3 vs G6-G7). Quantification of immunofluorescence for IL-1β (H) and 
NF-κB p65 (I). All measurements are the average ± S.E.M. of 250-300 motor neurons from four 
to five sections per animal. Each group was comprised of four to five mice. ** p< 0.01 and * p< 
0.05 vs TG CTL (unpaired t-test). Scale bar: 50 µm at low magnification and 25 µm at high 
magnification. 
 
Figure 8. Benfotiamine and its metabolites activate the Nrf2/ARE pathway. BFT treatment 
induced transcription of Nrf2/ARE genes in WT but not Nrf2 KO MEFs. Nrf2 WT/KO MEFs 
were treated with solvent (Control, 1:1 pyridine:water) or 50 uM (50) or 100 uM (100) of either 
BFT (A) or thiamine (B). GSR and HO1 mRNA was measured after 3 h incubation with the 
drugs, where as GCLM and NQO1 were measured after 8 h of incubation. Thiamine did not have 
any effect on the genes examined except for GSR at the highest dose (100 µM) after 8 h 
treatment. Experiments were conducted in three biological replicates, each in six technical 
replicates. * p< 0.05 when compared to WT control. (C) BFT, its metabolites, and thiamine were 
tested for Neh2-luc activation (C) in Neh2-luc expressing SH-SY5Y cells and in ODD-luc assay 
(D) at two different concentrations (50 and 100 µM). BFT and its metabolites but not thiamine 
showed Neh2-luc activation whereas none of the compounds activated ODD-luc. The luciferase 
activity was measured and depicted as percentage fold activity. Data are mean ± S.E.M. from 
three independent experiments. * p< 0.05 compared to control. # p< 0.05 relative to 50 µM of 
respective drug. (E) Effects of BFT and its metabolites on GCLM, NQO1, and HO1 ARE genes 
in Nrf2 WT and KO MEFs. The levels of mRNA were measured after 4 h of incubation with 
control (1:1, pyridine: water) or 100 µM of either thiamine, BFT, s-BT, o-BT or z-BT. 
Measurements were conducted at least three times for all conditions. * p<0.05 compared to WT 
control. (F) WT C57BL/6 mice were treated for 3 h with either vehicle or 1250 mg/kg of 
thiamine, BFT, s-BT, o-BT or z-BT through oral gavage. Gene expression changes were 
assessed by quantitative RT-PCR. All measurements are the averages ± S.E.M. from n = five to 
six mice per group. *** p< 0.001, ** p< 0.01 and * p< 0.05 relative to control. Statistical 
analyses were performed by two-way ANOVA with post-hoc analysis by Dunnett's multiple 
comparison test.  
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Fig 1 - Lifespan, behavior and cell counts  
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Fig 4 - Mitochondrial assessment  
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Fig 8 - Nrf2/ARE genes  
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